Ok here are the main points I picked up. Bear in mind that this...

Ok here are the main points I picked up. Bear in mind that this interview was done in August last year. Brr have been in contact with CEO, so we can expect another interview soon, hopefully.

"This technology allows proteins and other biological entities to be captured and oriented to
optimise biological testing, better than currently possible eg in diagnosis of disease in path labs.

Mix&go - how it works. At the moment the process is that it starts with magnetic microparticles and antibodies or
proteins are bound with those microparticles. That process is currently done at elevated temperatures and it takes a long time and oftentimes the results are variable and re-working is required to get the product that's produced to be somewhat standard. Mix & Go has been named
because that's exactly what you do. You take the beads, you mix it with the Mix & Go solution and
then add the protein or antibody. That's as easy as it is, it takes minutes rather than days. And the result (after feedback from bead manufacturers) is that the beads are far easier to handle and the process saves them days in terms of manufacturing time.

The diagnostic area offers best chance of immediate sources of revenue. Most likley revenue will be
coming from a royalty stream. The royalty could come from a bead manufacturer or an invitro diagnostic supplier.

Research & development costs - all of the R&D to date has been done internally and they are now at the stage that they have sufficiently robust "recipes" that other people can use the technology very effectively so that they can achieve the same results. Mix&Go is going out to potential end-users or potential licensees to look at in their own hands to see whether they can generate the same
high-quality results as achieved in testing. So far they have been able to demonstrate the capabilities of the technology themselves. This has led to the company having further discussions on the potential for royalties and ongoing revenue stream. Revenues are already being generated from test development capabilities and that will continue. Optimism is high that licensing revenues will
soon start to flow in, which will counterract current cash burn of company.

Focus has been on Mix&Go, as this is the closest product to be ready for market. Other products in development will further raise revenues, opening up a whole new area of commercial possibilites for the company, especially in diagnostic testing."